Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source documentNasdaq· April 10, 2026

Novel Drugs Approved By The FDA In 2025

View original at nasdaq.com
Novel Drugs Approved By The FDA In 2025 (RTTNews) - The U.S. Food and Drug Administration (FDA) in 2025 approved 46 novel drugs, including 34 new molecular entities (NMEs) and 12 biologics…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

Data points we hold from this source

U.S. Food and Drug Administration · accelerated approvals11 drugs
U.S. Food and Drug Administration · biologics approved12 biologics
U.S. Food and Drug Administration · fast track designations18 drugs
U.S. Food and Drug Administration · first in class drugs20 drugs
U.S. Food and Drug Administration · new molecular entities approved34 NMEs
U.S. Food and Drug Administration · novel drugs approved46 drugs
U.S. Food and Drug Administration · priority reviews21 drugs
U.S. Food and Drug Administration · rare disease drugs23 drugs
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com